A Phase II, Prospective, Open-Label, Single-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine Candidate MVC-COV1901, CT-COV-21 Sub-study
Latest Information Update: 15 Jun 2022
At a glance
- Drugs MVC COV1901 (Primary) ; Aluminium hydroxide; CpG; Protein S
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Medigen Vaccine Biologics
- 10 Jun 2022 Status changed from active, no longer recruiting to completed.
- 27 Jan 2022 Planned End Date changed from 1 Feb 2022 to 1 Apr 2022.
- 05 Oct 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Nov 2021.